Saturday 17 October 2026
Export MGRX’s income statement to Excel — free account
Mangoceuticals, Inc.
MGRX Healthcare Health Information Services
Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024. In the quarter to June 2026, revenue fell 59.1%, EPS grew 84.2% and free cash flow grew 79.3%, each against the same quarter a year earlier.
0.30
0.02
−6.25%
Follow MGRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 4 |
+8 more TTM periods Free account |
| (95.09%) | (113.90%) | (141.66%) | (136.16%) | ||
| (86.27%) | (106.11%) | (131.23%) | (126.56%) | ||
ROIC |
(62.76%) | (77.92%) | (82.19%) | (78.16%) | |
Return on Tangible Assets |
1,312.11% | 3,668.22% | (3,134.38%) | 9,711.81% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.23) | (0.30) | (0.58) | (0.51) | |
Free Cash Flow |
(3.89) | (4.89) | (5.85) | (5.90) | |
| Other line items | |||||
Cash ROIC |
(30.51%) | (35.80%) | (35.06%) | (36.41%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.17 | 0.23 | 0.33 | 0.29 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
2,276.67 | 980.12 | 739.76 | 1,046.55 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
3,954.90% | 4,014.69% | 3,666.97% | 3,807.69% | |
Share Based Compensation of Revenue |
1,989.28% | 2,259.36% | 2,350.15% | 2,373.50% | |
Interest Coverage |
(32.89) | (141.49) | (174.23) | 212.07 | |
Operating CF/Net income |
0.26 | 0.25 | 0.28 | 0.30 | |
Depreciation/Fixed assets |
1,768.69 | 1,893.80 | 1,646.72 | 766.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.02 | 0.03 | 0.05 | 0.04 | |
Operating CF per Share |
(0.23) | (0.30) | (0.58) | (0.51) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026